← Russell 3000 cross-section

MIRM Mirum Pharmaceuticals, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-05, not restated
Healthcare

Scale

Market cap
$6.0bn
Revenue TTM
$618m
Net income TTM
$-860m
Free cash flow
$-229m
Composite score
Sector rank
#963

Valuation

P / E
EV / EBITDA
EV / sales
9.0
FCF yield
-3.80%
Earnings yield vs 10-yr
-19.03pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-139.2%
EBITDA margin
-130.7%
ROE
8,253.8%
ROIC
Revenue growth
44.0%

Insider activity, last 90 days

Net open-market
$-14.16m
Buyers
0
Sellers
4

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

We expect total product sales of our approved medicines will continue to increase on an annual basis. For our current approved products, we expect cost of sales to increase in the future mainly due to variable costs associated with increased product sales such as royalties payable and inventory costs. Selling, General and Administrative Expense Sales and marketing expense, which is a component of selling, general and administrative expense, primarily consisted of employee-related expenses for our sales group, brand marketing, patient support groups and pre-commercialization expenses related to our product candidates. …Mirum Pharmaceuticals, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-05

Read the full passage →